



## Spruce Biosciences to Participate in the RBC Capital Markets Global Healthcare Conference

May 13, 2021

SAN FRANCISCO--(BUSINESS WIRE)--May 13, 2021-- [Spruce Biosciences, Inc.](#) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Richard King, Chief Executive Officer, will participate in a virtual fireside chat at the RBC Capital Markets Global Healthcare Conference on May 19, 2021 at 5:25pm EDT.

Interested parties can access the live webcast for the conference from the [Events](#) section of the company's investor relations website at <https://investors.sprucebiosciences.com>. An archived replay of the webcast will be available after the conclusion of the live presentation for approximately 30 days.

### About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. Spruce is also developing tildacerfont for women suffering from a rare form of polycystic ovary syndrome (PCOS) with primary adrenal androgen excess, representing 3-5% of females with PCOS (estimated to be 150,000 to 200,000 patients in the United States). To learn more, visit [www.sprucebiosciences.com](http://www.sprucebiosciences.com) and follow us on Twitter [@Spruce\\_Bio](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210513005039/en/): <https://www.businesswire.com/news/home/20210513005039/en/>

### Media:

Will Zasadny  
Canale Communications  
(619) 961-8848  
[will.zasadny@canalecomm.com](mailto:will.zasadny@canalecomm.com)  
[media@sprucebiosciences.com](mailto:media@sprucebiosciences.com)

### Investors

Xuan Yang  
Solebury Trout  
(415) 971-9412  
[xyang@soleburytrout.com](mailto:xyang@soleburytrout.com)  
[investors@sprucebiosciences.com](mailto:investors@sprucebiosciences.com)

Source: Spruce Biosciences, Inc.